These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 28158504)
41. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053 [TBL] [Abstract][Full Text] [Related]
42. Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database. Aurpibul L; Kariminia A; Vibol U; Fong MS; Le ON; Hansudewechakul R; Bunupuradah T; Kurniati N; Chokephaibulkit K; Kumarasamy N; Wati DK; Yusoff NKN; Razali KAM; Nallusamy RA; Sohn AH; Lumbiganon P; Pediatr Infect Dis J; 2018 Aug; 37(8):788-793. PubMed ID: 29846357 [TBL] [Abstract][Full Text] [Related]
43. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858 [TBL] [Abstract][Full Text] [Related]
44. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome. Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279 [TBL] [Abstract][Full Text] [Related]
45. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. Dezanet LNC; Kassime R; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A Clin Infect Dis; 2022 Mar; 74(6):1012-1021. PubMed ID: 34197574 [TBL] [Abstract][Full Text] [Related]
46. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697 [TBL] [Abstract][Full Text] [Related]
47. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693 [TBL] [Abstract][Full Text] [Related]
48. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. Coffin CS; Osiowy C; Myers RP; Gill MJ J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393 [TBL] [Abstract][Full Text] [Related]
49. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa. Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K; J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291 [TBL] [Abstract][Full Text] [Related]
50. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. De Luca A; Bugarini R; Lepri AC; Puoti M; Girardi E; Antinori A; Poggio A; Pagano G; Tositti G; Cadeo G; Macor A; Toti M; D'Arminio Monforte A; Arch Intern Med; 2002 Oct; 162(18):2125-32. PubMed ID: 12374521 [TBL] [Abstract][Full Text] [Related]
51. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461 [TBL] [Abstract][Full Text] [Related]
52. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA; J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660 [TBL] [Abstract][Full Text] [Related]
53. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada? Rana U; Driedger M; Sereda P; Pan S; Ding E; Wong A; Walmsley S; Klein M; Kelly D; Loutfy M; Thomas R; Sanche S; Kroch A; Machouf N; Roy-Gagnon MH; Hogg R; Cooper CL; BMC Infect Dis; 2019 Nov; 19(1):982. PubMed ID: 31752729 [TBL] [Abstract][Full Text] [Related]
54. Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia. Chisenga CC; Musukuma K; Chilengi R; Zürcher S; Munamunungu V; Siyunda A; Ojok D; Bauer S; Wandeler G; Vinikoor M; J Clin Virol; 2018 Jan; 98():5-7. PubMed ID: 29175231 [TBL] [Abstract][Full Text] [Related]
55. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa. Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K; Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068 [TBL] [Abstract][Full Text] [Related]
56. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819 [TBL] [Abstract][Full Text] [Related]
58. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414 [TBL] [Abstract][Full Text] [Related]
59. The treatment outcome of chronic HBV infection among HBV/HIV co-infected and HBV mono-infected patients. Karić U; Milošević I; Pešić-Pavlović I; Salemović D; Stojković M; Jevtović D Int J STD AIDS; 2020 Jan; 31(1):38-45. PubMed ID: 31838949 [No Abstract] [Full Text] [Related]
60. An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand. Peters PJ; McNicholl JM; Raengsakulrach B; Wasinrapee P; Mueanpai F; Ratanasuwan W; Intalapaporn P; Drobeniuc J; Ramachandran S; Thai H; Xia GL; Kamili S; Khudyakov Y; Weidle PJ; Teo CG; McConnell MS J Int Assoc Provid AIDS Care; 2013; 12(5):349-53. PubMed ID: 23792710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]